Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Guy Lerebours"'
Autor:
Esteban López de Sá, Guy Lerebours, Michel Komajda, Benoit Tyl, Matthieu Pannaux, Aurélie de Montigny, Claire Varin, Jeffrey S. Borer, José Luis López Sendón
Publikováno v:
Circulation. Heart failure. 13(7)
Background: The usefulness of adjudication by central end point committees (CECs) is poorly assessed in heart failure (HF) trials. We aimed to assess its impact on the outcome of the SHIFT trial (Systolic HF Treatment With the If Inhibitor Ivabradine
Autor:
Jeffrey S. Borer, Karl Swedberg, Ariane Dubost-Brama, Luigi Tavazzi, Guy Lerebours, Michael Böhm, Ian Ford, Michel Komajda
Publikováno v:
The Lancet. 376:886-894
Raised resting heart rate is a marker of cardiovascular risk. We postulated that heart rate is also a risk factor for cardiovascular events in heart failure. In the SHIFT trial, patients with chronic heart failure were treated with the selective hear
Autor:
Guy Lerebours
Publikováno v:
médecine/sciences. 23:657-662
The normal cardiac rhythm originates in a specialized region of the heart, the sinus node that is part of the nodal tissue. The rhythmic, impulse initiation of sinus node pacemaker cells results from a spontaneous diastolic depolarization that is ini
Publikováno v:
Heart Drug. 5:14-20
Elevated heart rate (HR) contributes to myocardial ischaemia, especially when coronary blood supply is restricted, and is recognised as an independent risk factor for increased morbidity and mortality. Heart beat is driven by cellular automaticity of
Publikováno v:
Heart Drug. 5:21-24
Elevated resting heart rate is linked to an increase in both cardiovascular and all-cause mortality, and agents that reduce heart rate have obvious applications in improving the prognosis of coronary artery disease and heart failure. In this short re
Publikováno v:
Circulation. 107:817-823
Background— Heart rate reduction should benefit patients with chronic stable angina by improving myocardial perfusion and reducing myocardial oxygen demand. This study evaluated the antianginal and antiischemic effects of ivabradine, a new heart ra
Publikováno v:
Journal of Cardiovascular Pharmacology. 36:570-576
Restoration of flow-dependent coronary artery dilation by angiotensin-converting enzyme inhibition (ACEI) has been demonstrated in patients with hypertension. The aim of the present study was to evaluate whether dilation of conductance coronary arter
Autor:
Rémi Varin, Jean-Paul Henry, Christian Thuillez, Vincent Richard, Fabienne Tamion, Guy Lerebours, Paul Mulder, Françoise Lallemand
Publikováno v:
Circulation. 102:351-356
Background —Chronic heart failure (CHF) impairs the endothelium-dependent, flow-mediated dilation (FMD) of small arteries. However, whether chronic angiotensin-converting enzyme (ACE) inhibition affects the impairment of FMD in CHF is unknown. We i
Autor:
Rémi Varin, Fabienne Tamion, Corinne Devaux, Paul Mulder, Guy Lerebours, Jean-Paul Henry, Françoise Lallemand, Christian Thuillez, Vincent Richard
Publikováno v:
Circulation. 99:2951-2957
Background —Flow-mediated dilatation (FMD) of the peripheral arteries may be impaired in chronic heart failure (CHF), and this could contribute to the increased peripheral resistance and exercise intolerance that occur with this disease. Physical e
Publikováno v:
American Journal of Hypertension. 8:13S-18S
In normal coronary arteries, increased flow velocity induces endothelium-dependent dilation, and dilation in response to sympathetic stimulation evoked by the cold pressor test is partly due to increased flow velocity. In arterial hypertension, angio